BSE
506820

AstraZeneca Pharma India Limited

Drug Manufacturers - Major
Healthcare

Prices are adjusted according to historical splits.

AstraZeneca Pharma India Limited Stock Price

Vitals

Today's Low:
₹4370
Today's High:
₹4555.75
Open Price:
₹4511.95
52W Low:
₹2926.6176
52W High:
₹4346
Prev. Close:
₹4511.9
Volume:
1309

Company Statistics

Market Cap.:
₹107.86 billion
Book Value:
162.084
Revenue TTM:
₹8.22 billion
Operating Margin TTM:
11.91%
Gross Profit TTM:
₹5.20 billion
Profit Margin:
9.89%
Return on Assets TTM:
8.95%
Return on Equity TTM:
22.12%

Company Profile

AstraZeneca Pharma India Limited had its IPO on under the ticker symbol 506820.

The company operates in the Healthcare sector and Drug Manufacturers - Major industry. AstraZeneca Pharma India Limited has a staff strength of 1,325 employees.

Stock update

Shares of AstraZeneca Pharma India Limited opened at ₹4511.95 at the start of the last trading session i.e. 2023-09-13.

The stocks traded within a range of ₹4370 - ₹4555.75, and closed at ₹4475.2.

This is a -0.81% slip from the previous day's closing price.

A total volume of 1,309 shares were traded at the close of the day’s session.

In the last one week, shares of AstraZeneca Pharma India Limited have increased by +4.27%.

AstraZeneca Pharma India Limited's Key Ratios

AstraZeneca Pharma India Limited has a market cap of ₹107.86 billion, indicating a price to book ratio of 29.3481 and a price to sales ratio of 13.0341.

In the last 12-months AstraZeneca Pharma India Limited’s revenue was ₹8.22 billion with a gross profit of ₹5.20 billion and an EBITDA of ₹1.13 billion. The EBITDA ratio measures AstraZeneca Pharma India Limited's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, AstraZeneca Pharma India Limited’s operating margin was 11.91% while its return on assets stood at 8.95% with a return of equity of 22.12%.

In Q3, AstraZeneca Pharma India Limited’s quarterly earnings growth was a positive 82.7% while revenue growth was a positive 0.5%.

AstraZeneca Pharma India Limited’s PE and PEG Ratio

Forward PE
0
Trailing PE
154.2267
PEG

Its diluted EPS in the last 12-months stands at ₹32.504 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into AstraZeneca Pharma India Limited’s profitability.

AstraZeneca Pharma India Limited stock is trading at a EV to sales ratio of 12.7223 and a EV to EBITDA ratio of 80.357. Its price to sales ratio in the trailing 12-months stood at 13.0341.

AstraZeneca Pharma India Limited stock pays annual dividends of ₹4 per share, indicating a yield of 0.09% and a payout ratio of 9.1%.

Balance sheet and cash flow metrics

Total Assets
₹9.85 billion
Total Liabilities
₹3.84 billion
Operating Cash Flow
₹181.10 million
Capital Expenditure
₹85.20 million
Dividend Payout Ratio
9.1%

AstraZeneca Pharma India Limited ended 2024 with ₹9.85 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹9.85 billion while shareholder equity stood at ₹5.89 billion.

AstraZeneca Pharma India Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹3.84 billion in other current liabilities, 50000000.00 in common stock, ₹5.84 billion in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹0 and cash and short-term investments were ₹5.11 billion. The company’s total short-term debt was ₹0 while long-term debt stood at ₹0.

AstraZeneca Pharma India Limited’s total current assets stands at ₹8.35 billion while long-term investments were ₹0 and short-term investments were ₹105.70 million. Its net receivables were ₹1.08 billion compared to accounts payable of ₹0 and inventory worth ₹1.90 billion.

In 2024, AstraZeneca Pharma India Limited's operating cash flow was ₹181.10 million while its capital expenditure stood at ₹85.20 million.

Comparatively, AstraZeneca Pharma India Limited paid ₹0.09 in dividends in 2024.

Other key metrics

Current Trading Price
₹4475.2
52-Week High
₹4346
52-Week Low
₹2926.6176
Analyst Target Price

AstraZeneca Pharma India Limited stock is currently trading at ₹4475.2 per share. It touched a 52-week high of ₹4346 and a 52-week low of ₹4346. Analysts tracking the stock have a 12-month average target price of .

Its 50-day moving average was ₹3973.67 and 200-day moving average was ₹3501.23 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 8167.8% of the company’s stock are held by insiders while 425.7% are held by institutions.

Frequently Asked Questions About AstraZeneca Pharma India Limited

The stock symbol (also called stock or share ticker) of AstraZeneca Pharma India Limited is 506820

The IPO of AstraZeneca Pharma India Limited took place on

Similar Industry Stocks (Drug Manufacturers - Major)

Last Price
Chg
Chg%
CONX Corp (CONXW)
₹0.15
-0
-2.53%
₹0.51
0.01
+2%
₹167.39
-0.3
-0.18%
Figs Inc (FIGS)
₹5.59
0.01
+0.18%
₹1416.15
-29.2
-2.02%
₹21.45
-0.54
-2.46%
Zenvia Inc (ZENV)
₹1.1
0.03
+2.8%
₹15.68
0
0%
₹111.8
-8.7
-7.22%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
₹0.14
0.07
+100%
₹0.12
0.04
+45.29%
₹0.96
0.05
+5.4%
₹1.34
-0.35
-20.71%
Humbl Inc (HMBL)
₹0
0
0%

Top Gainers

Last Price
Chg
Chg%
₹0
0
+172200%
₹0
0
+51200%
₹283
280.03
+9428.62%
₹11.2
10.57
+1667.68%
Latch Inc (LTCHW)
₹0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
₹0.19
-123.15
-99.85%
₹0
-0.11
-99.55%
₹0
-0
-97.96%
₹0
-0.01
-93.94%
₹0.01
-0.06
-92.24%

About

AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and distributes pharmaceutical products in India and internationally. It manufactures and sells medicines under the Brilinta, Axcer, Forxiga, Oxra, Gledepa, Xigduo, Symbicort, Onglyza, Kombiglyze, Tagrisso, Lynparza, Zoladex, QTERN, and Imfinzi brand names. The company offers products in the areas of cardiovascular, renal, metabolic, oncology, antidiabetic, respiratory, inflammation, and autoimmunity diseases. It also provides clinical trial services. The company was founded in 1979 and is headquartered in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.

Address

Manyata Embassy Business Park, Bengaluru, India, 560045